Clinical Trials In Rare Diseases - Virtual Conference
Virtual Event
8th-9th December, 2020
Clinical Trials In Rare Diseases - Virtual Conference
This online event will explore the challenges when working with Orphan Drugs and Rare Diseases, and the benefits from a development viewpoint. It will explore the benefits of early planning and engagement with the FDA, as well as looking into case studies on what has and has not been an effective strategy in Rare Disease trials.
With over 40 solution providers the virtual meeting will be a perfect platform to reconnect with current business partners, meet new vendors and discover which new technologies are being employed to improve your Rare Disease clinical trials.
At each virtual event we create a welcoming networking environment and an educational program packed with the latest case studies, techniques and providers to set your trial apart. The Arena team will bring some of the leading voices in Rare Disease who are best situated to answer your questions and provide you the insight you need to successfully run your trial.
A FANTASTIC NETWORK OF YOUR PEERS AND COLLEAGUES RIGHT AT A TAP OR CLICK OF A BUTTON
Simply register, login on the day and get ready to connect and learn. With the right network at your fingertips, learning and connecting have never been so easy.
💻 Watch live and recorded thought leadership presentations
🗣️ Take part in live Q&A with industry experts from across the globe
👩💻 One-to-one & group video chat with each solution provider
🤝 Chat & network with anyone on the platform
📊 Take part in our interactive polls
👥 Join live panel debates and discussions
🛍️ Download resources from solution providers to your event bag
TESTIMONIALS
-
‘That was a superb day, it feels like we’ve been at a real, in person, conference!’ Worldwide Clinical Trials
-
‘A great event, I met more people than I do at an in-person event and I’ve got loads of follow ups’ Conversis
-
‘The whole setting is actually very well accomplished! Thanks again for the invitation!’ Apogenix AG

Jennifer McNary
Patient Advocate,
Biography:
Session Details: FIRESIDE CHAT: Patient focus: how to keep the patient at the forefront of your clinical trial design 07-12-2020, 1:30 pm View In Agenda

Jill Dolgin
Executive Director, Patient Advocacy,AGTC
Biography:
Session Details: PANEL DISCUSSION: Patients at the center of rare disease clinical trials 07-12-2020, 2:15 pm View In Agenda

Mukesh Kumar
Chief Executive Officer,Akan Biosciences

Karl-Johan Myren
Senior Director, Health Economics and Outcomes Research EMEAC,Alexion Pharmaceuticals
Biography:
Session Details: PANEL DISCUSSION: Patients at the center of rare disease clinical trials 07-12-2020, 2:15 pm View In Agenda

Wendy Erler
Vice President, Patient Experience/STAR & Patient Experience and Advocacy,Alexion Pharmaceuticals
Biography:
Session Details: FIRESIDE CHAT: Patient focus: how to keep the patient at the forefront of your clinical trial design 07-12-2020, 1:30 pm ROUNDTABLE DISCUSSION: Patient centricity and recruitment: overcoming challenges around access to rare disease trials 08-12-2020, 12:30 pm View In Agenda

Illana Gozes
Professor Emerita,Tel Aviv University, CSO ATED Therapeutics Ltd
Biography: Professor of Clinical Biochemistry the Lily and Avraham Gildor Chair for the Investigation of Growth Factors, Head of the Elton Laboratory for Molecular Neuroendocrinology, Department of Human Molecular Genetics and Biochemistry, Sackler Faculty of Medicine, Sagol School of Neuroscience and Adams Super Center for Brain Studies, Tel Aviv University. Former Director, the Adams Super Center for Brain Studies & the Edersheim Levie-Gitter Institute for Functional Brain Imaging. Serves as Editor-in-Chief of the Journal of Molecular Neuroscience. The inventor of CP201 and CP102. Holds a B.Sc. from Tel Aviv University and a Ph.D. from the Weizmann Institute of Science.
Session Details: CASE STUDY: Working with a rare disease in clinical development 07-12-2020, 11:30 am Live Q&A with Illana Gozes 07-12-2020, 11:50 am View In Agenda

Jay Russak
Director, Clinical Development,Dicerna Pharmaceuticals
Biography:
Session Details: PANEL DISCUSSION: Patients at the center of rare disease clinical trials 07-12-2020, 2:15 pm CASE STUDY: Using data effectively in studies with smaller numbers of patients 07-12-2020, 4:00 pm Live Q&A with Jay Russak 07-12-2020, 4:20 pm View In Agenda

Dr. Lidia V. Gabis
MD MBA, Director, The Weinberg Child Development Center and Keshet Center for Autism,Safra Children's Hospital at Sheba, and Tel Aviv University, Israel
Biography:
Session Details: CASE STUDY: Precision personalised approach to autism related rare disorders 07-12-2020, 12:30 pm Live Q&A with Dr Lidia Gabis 07-12-2020, 12:50 pm View In Agenda

Mimi Choon-Quinones
Founder and Chairman,Partners For Patients, PfP.NGO
Biography:
I am passionate about advocating for patients by improving healthcare policies, advancing medical knowledge, driving innovative digital solutions in the quest to increase medical access to treatments for patients. I feel it is one of my responsibilities to support every patient around the world who struggles to get access to medicines.
Session Details: OPENING KEYNOTE: Assessing the impact of COVID-19 on rare disease clinical trials and the outlook for 2021 07-12-2020, 9:00 am Live Q&A with Mimi Choon-Quinones 07-12-2020, 9:20 am PANEL DISCUSSION: Regulatory affairs in international markets: assessing the differences between conducting a rare disease study in the UK, Europe, the US and beyond 08-12-2020, 10:00 am View In Agenda

Dr. Ian Hodgson
PhD, Clinical Advisor Consultant,Mereo BioPharma Group
Biography:
Session Details: CLOSING KEYNOTE: Moving forward for rare disease studies: are decentralized and virtual trials a permanent solution? 08-12-2020, 2:30 pm Live Q&A with Ian Hodgson 08-12-2020, 2:50 pm View In Agenda

Cesare Spadoni
Founder and Chief Operating Officer,Oncoheroes Biosciences
Biography: Cesare is co-founder and Chief Operating Officer of Oncoheroes Biosciences Inc., a Boston-based biotech company focused on pediatric oncology drug development. Cesare has more than 20 years of experience in the drug development field, in both scientific and commercial roles. Previously, he held senior positions at AMRI, Aptuit Laurus, ThalesNano and Auxiliis. Cesare started his career as research scientist in a pharmaceutical company (Eisai, London) and in academia (Institute of Enzymology, Budapest). Following the death of his first daughter Laura to cancer, Cesare set up aPODD Foundation, a London-based charity focused on accelerating paediatric oncology drug development. As aPODD’s chairman he is actively involved on a pro-bono basis in drug repurposing projects, advocacy efforts and research collaborations. Cesare holds an MSc in Applied Molecular Biology and a PhD in Neurosciences from UCL, University of London, as well as an MBA from the Central European University, Budapest.
Session Details: Drug development for rare childhood cancers 07-12-2020, 3:00 pm Live Q&A with Cesare Spadoni 07-12-2020, 3:20 pm View In Agenda

Scott Schliebner
Senior Vice President, Center for Rare Diseases,PRA Health Sciences
Biography: Mr. Schliebner is a clinical strategist with a 25+ year background in clinical drug development focused on rare diseases, orphan drugs, and advanced therapeutics. He develops innovative solutions and strategic considerations to help overcome the operational, logistical, and ethical challenges inherent to conducting research in challenging patient populations. Mr. Schliebner’s efforts are focused on patient-centered approaches to drug development; reducing the burden of clinical trial participation; and leveraging virtual and de-centralized paradigms to bring new therapies to patients faster. Mr. Schliebner also serves as the Co-Chair of Global Genes’ Corporate Alliance, and serves on the Board of Uplifting Athletes. He holds a Master’s Degree in Public Health (MPH) from the University of Utah School of Medicine, and completed a Graduate Research Fellowship at The National Institutes of Health.
Session Details: Rare Disease Drug Development: A New Clinical Paradigm 07-12-2020, 10:30 am Rare Disease Drug Development: A New Clinical Paradigm 08-12-2020, 11:00 am Live Q&A with Scott Schliebner 08-12-2020, 11:20 am View In Agenda

Anne Bruns
Director, Clinical Patient Advocacy,PTC Therapeutics
Biography:
Session Details: Patient Centric Approach in Clinical Trials 08-12-2020, 2:00 pm Live Q&A with Anne Bruns and Vij Sethilnathan 08-12-2020, 2:20 pm View In Agenda

Ricardo Hermosilla
Translational Medicine Leader,Roche
Biography:
Session Details: PANEL DISCUSSION: Regulatory affairs in international markets: assessing the differences between conducting a rare disease study in the UK, Europe, the US and beyond 08-12-2020, 10:00 am Best practice for patient engagement throughout a rare disease study 08-12-2020, 1:00 pm Live Q&A with Ricardo Hermosilla 08-12-2020, 1:20 pm View In Agenda

James Richardson
Country Medical Director, UK and Ireland,Sarepta Therapeutics
Biography:
Session Details: CASE STUDY: Challenges associated with in vivo gene therapy 08-12-2020, 9:00 am Live Q&A with James Richardson 08-12-2020, 9:20 am View In Agenda

Jigar Chheda
Clinical Project Leader & Portfolio Lead, Rare Genetic Diseases and Rare Blood Disorders,Sanofi Genzyme
Biography:
Session Details: ROUNDTABLE: Outsourcing challenges: finding a CRO best suited for your rare disease study 07-12-2020, 10:00 am View In Agenda

Boaz Barak
Assistant Professor,Tel Aviv University
Biography:
Session Details: From bench to bedside: taking a drug from the lab to a clinic to treat Williams Syndrome 08-12-2020, 11:13 am Live Q&A with Boaz Barak 08-12-2020, 11:50 am View In Agenda

Suki Malhi
Senior Director, Clinical Affairs,Zogenix, Inc.
Biography:
Session Details: CASE STUDY: Direct-to-patient shipments in orphan drug trials and how to navigate hurdles to deliver drugs safely and efficiently 07-12-2020, 3:30 pm Live Q&A with Suki Malhi 07-12-2020, 3:50 pm View In Agenda

Kelly Millhaem
Sr. Clinical Trial Manager, Associate Director Clinical Operations,Medpace
Biography:
Session Details: Support for Rare Disease Site Staff through COVID-19 and beyond 08-12-2020, 12:00 pm Live Q&A with Kelly Millhaem 08-12-2020, 12:20 pm View In Agenda

Asad Balal
International Head of Clinical Client Services - Life Sciences,Volt International
Biography:
Asad heads up the life science business globally for Volt International. He specialises in helping companies with their staffing needs across the globe on a permanent and contract basis.
Asad has over 105 recommendations on LinkedIn from various VP’s, Head’s & Directors of Clinical at Biotech, Clinical Stage, Pharmaceutical & CRO companies across the globe.
Vertical Expertise:
Clinical Operations, Clinical Research, Clinical Affairs & Clinical Development.
Client’s Expertise:
Pharmaceutical Companies, Biotechnology Companies, Medical Device Companies, Clinical Research Organisations, Clinical Stage Biopharma Companies & Start Up Patient Recruitment Companies.
https://www.linkedin.com/in/asadbalal/Session Details: Clinical Trials within Rare Diseases Post Covid-19 07-12-2020, 1:00 pm Live Q&A with Volt 07-12-2020, 1:20 pm View In Agenda

Kaitlyn Townsey
Associate Director of Product Innovation,Axiom Real-Time Metrics
Biography:
Kaitlyn Townsley is the Associate Director of Product Innovation at Axiom Real-Time Metrics Inc., where she continually innovates Fusion eClinical Suite and related technologies to support the evolving technological needs of Clinical Trials as Studies increase in complexity, maintaining the balance between an easy and intuitive platform, and providing Sponsors with the complex tools they require to run their Clinical Programs.
Session Details: Rare Disease Studies - Data Challenges & Solutions 08-12-2020, 1:30 pm Live Q&A with Kaitlyn Townsley 08-12-2020, 1:50 pm View In Agenda

Andrew Schachter
Founder & CEO,Axiom Real-Time Metrics
Biography: As Founder and Chief Executive Officer of Axiom Real-Time Metrics, Andrew Schachter delivers the visionary leadership integral to the company's 20 years of eClinical technology and Managed services success. Under his leadership, Axiom has grown into a well-established and recognized innovator and leader in the small-to-medium life science Clinical solutions landscape. His expertise and profound understanding of complex clinical studies have transformed the Axiom global team into a devoted and virtuous leader in the industry. Over the past 20 years, Schachter's passion for innovating technology solutions continues to drive Axiom to empower smarter and faster clinical studies and yield better study results for helping patients worldwide. Today, Axiom's state-of-the-art unified eClinical Suite Fusion has over 15 powerful and highly configurable modules. In addition, Axiom also offers global clients intelligent Data Management, Data Analytics, Pharmacovigilance & BioStats services.
Session Details: View In Agenda



Citation Healthcare Labels
SPONSORSHIP OPPORTUNITIES
To enquire about sponsorship opportunities for the conference, please contact:
Alexander O’Leary
Portfolio Director – OCT EMEA and Pharma Packaging & Labelling Global
Arena International Events Group
T: +44 207 936 6690
E: alexanderoleary@arena-international.com
SPEAKING OPPORTUNITIES
To enquire about speaking opportunities for the conference, please contact:
Louisa Manning
Programme Director
ZOOM PHONE: +44 (0) 207 661 0906
E: louisa.manning@arena-international.com